These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 34925237)
1. Current and Potential Therapies Targeting Inflammation in NASH. Albhaisi S; Noureddin M Front Endocrinol (Lausanne); 2021; 12():767314. PubMed ID: 34925237 [TBL] [Abstract][Full Text] [Related]
2. Triggering and resolution of inflammation in NASH. Schuster S; Cabrera D; Arrese M; Feldstein AE Nat Rev Gastroenterol Hepatol; 2018 Jun; 15(6):349-364. PubMed ID: 29740166 [TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Pierantonelli I; Svegliati-Baroni G Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287 [TBL] [Abstract][Full Text] [Related]
4. Role of chronic inflammation in the pathogenesis of nonalcoholic steatohepatitis: lessons from a unique mouse model using melanocortin receptor-deficient mice. Itoh M; Suganami T; Ogawa Y Endocr J; 2021 Jul; 68(7):743-749. PubMed ID: 33967185 [TBL] [Abstract][Full Text] [Related]
5. Molecular pathways of nonalcoholic fatty liver disease development and progression. Bessone F; Razori MV; Roma MG Cell Mol Life Sci; 2019 Jan; 76(1):99-128. PubMed ID: 30343320 [TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease. Farrell GC; Haczeyni F; Chitturi S Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204 [TBL] [Abstract][Full Text] [Related]
9. Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)? Tariq Z; Green CJ; Hodson L Liver Int; 2014 Aug; 34(7):e180-90. PubMed ID: 24621397 [TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Kitade H; Chen G; Ni Y; Ota T Nutrients; 2017 Apr; 9(4):. PubMed ID: 28420094 [TBL] [Abstract][Full Text] [Related]
11. New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis. Mendez-Sanchez N; Cruz-Ramon VC; Ramirez-Perez OL; Hwang JP; Barranco-Fragoso B; Cordova-Gallardo J Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011790 [TBL] [Abstract][Full Text] [Related]
17. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Tillman EJ; Rolph T Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084 [TBL] [Abstract][Full Text] [Related]
18. Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis. Wang X; Hausding M; Weng SY; Kim YO; Steven S; Klein T; Daiber A; Schuppan D Antioxid Redox Signal; 2018 Jan; 28(2):87-109. PubMed ID: 28635324 [TBL] [Abstract][Full Text] [Related]
19. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Brown E; Hydes T; Hamid A; Cuthbertson DJ Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271 [TBL] [Abstract][Full Text] [Related]